Latest News and Press Releases
Want to stay updated on the latest news?
-
Paris, November 27, 2019, 8.30pm AB Science will host a live webcast on masitinib in severe asthma on Monday December 2, 2019 AB Science SA (NYSE Euronext – FR0010557264 – AB) is hosting a live...
-
Paris, November 26, 2019, 7pm AB Science will host a live webcast on masitinib in severe asthma on December 2, 2019 AB Science SA (NYSE Euronext – FR0010557264 – AB) is hosting a live webcast on...
-
Paris, 26 novembre 2019, 19h AB Science tiendra une web conférence sur le masitinibdans l’asthme sévère le 2 décembre 2019 AB Science SA (NYSE Euronext - FR0010557264 - AB) tiendra une web...
-
Paris, 25 November 2019, 8.15am Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis AB Science SA (NYSE Euronext - FR0010557264 - AB) is providing a summary of the live...
-
Paris, 25 novembre 2019, 8h15 Résumé de la conférence web dans la mastocytose systémique indolente avec les principaux leaders d’opinion AB Science SA (NYSE Euronext - FR0010557264 - AB) fournit le...
-
Paris, 22 novembre 2019, 8h15 Mise au point d’AB Science concernant l’article publié hier dans le journal Les Echos concernant l’enquête en cours de l’Autorité des Marchés Financiers AB Science SA...
-
Paris, November 22, 2019, 8.15am Clarification regarding the article published yesterday in the newspaper Les Echos related to the investigation by the French market authorities AB Science SA...
-
Paris, November 7, 2019, 8.30pm AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma Masitinib statistically significantly reduced the rate of...
-
Paris, 7 novembre 2019, 20h30 AB Science annonce des résultats de phase 3 positifs du masitinibdans l’asthme sévère Le masitinib a réduit de façon statistiquement significative le taux...
-
Paris, November 7, 2019, 8.30am AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA AB Science SA (NYSE Euronext - FR0010557264 - AB) announces today that the U.S. Food and...